A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

NCT02008279 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: 100 mg CNTO 3157
BIOLOGICAL: 300 mg CNTO 3157
BIOLOGICAL: 600 mg CNTO 3157
BIOLOGICAL: 300 mg CNTO 3157
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC